Related to FDA Clears Vertex’ Incivek as Combination Therapy for Chronic HCV Type 1

• FDA Clears Self-Injectable Formulation of BMS’ Rheumatoid Arthritis Drug
  
• Genentech Takes Another Shot at Convincing FDA to Maintain Avastin’s Metastatic Breast Cancer Approval
  
• FDA Issues Adventrx with Complete Response Letter for NSCLC Drug Candidate
  
• FDA Approves Gilead’s Single-Tablet Triple HIV Therapy Complera
  
• FDA Okays Gilead’s San Dimas, CA, Site for Continued Operation
  
• FDA Green-Lights Roche’s Melanoma Drug and Companion Diagnostic
  
• FDA Details Strategy for Overhauling Regulatory Science Used in Review Process
  
• Seattle Genetics’ Antibody-Drug Conjugate Receives FDA Okay to Treat Lymphomas
  
• FDA Sanctions Abbott's Genetic FISH Panel for Leukemia Prognosis
  
• FDA Issues Novartis with CRL Requesting Additional Safety Data on Gouty Arthritis Drug
  
• NuPathe Shares Plunge After Launch of Migraine Patch Delayed
  
• FDA Gives Amgen’s Prolia the Go-Ahead in Two Cancer Therapy-Induced Bone Loss Indications
  
• FDA Details “Reasonable and Feasible” Trial Design for Orexigen’s Obesity Drug Contrave
  
• FDA Clears Alexion’s Soliris for All Patients with Atypical Hemolytic Uremic Syndrome
  
• FDA Clears Lilly’s Cialis for Treating Symptoms of BPH in Men with or without Erectile Dysfunction
  
• BioHelix’ IsoAmp Near-Patient HSV Diagnostic Gets FDA 510(k) Clearance
  
• FDA Regulations Can Do as Much Harm as Good, According to GEN Poll
  
• FDA Clears Gen-Probe’s mRNA-Based HPV Assay for Use Alongside Pap Tests
  
• FDA Green-Lights Janssen's Anticoagulant for Reducing Stroke/Embolism in Nonvalvular AF Patients
  
• FDA Lifts Hold on Start of Helix’ Trial for Topical Treatment for Cervical Lesions